BioCentury | Dec 22, 2020
Regulation

Dec. 21-23 Regulatory Quick Takes: positive CHMP opinion for Pfizer-BioNTech COVID-19 vaccine; plus Urovant’s approval, a Feb. 9 adcomm for Keytruda in TNBC, NMPA reviewing a subcutaneous PD-L1, and more

...among international regulators. Zogenix’s Fintepla gains EU approval in DravetThe European Commission approved Fintepla fenfluramine from Zogenix Inc....
BioCentury | Dec 5, 2020
Product Development

Dec. 4 Quick Takes: Zogenix in Dravet deal with start-up; plus updates from BioCryst, Takeda, AB Science, Sutro, Lilly, Cedars-Sinai

...suppression. Tevard is eligible for $70-$100 million in milestones for each program. FDA has approved Zogenix's...
...Folate receptor 1 BC Staff maribavir (TAK-620, SHP620, 1263W94, Camvia) Masiviera, masitinib (AB1010, masican, masipro) STRO-002 bamlanivimab, LY-CoV555 (LY3819253) BioCryst Pharmaceuticals Inc. Zogenix Takeda Sutro...
BioCentury | Nov 12, 2020
Management Tracks

ObsEva, Korro bring in new CEOs; plus Cerebral, Spartan, Apnimed and Micronoma

...as chairman and Stephen Collins as a board member. Farr is co-founder, president and CEO of Zogenix Inc....
...VP of laboratory operations at DermTech Inc. (NASDAQ:DMTK). Danielle Golovin Aerpio Pharmaceuticals Inc. Nektar Therapeutics Spartan Bioscience Inc. ObsEva S.A. Cerebral Therapeutics Inc. Zogenix Inc. Xalud...
BioCentury | Oct 28, 2020
Deals

Out of the Arena: With $56M round, spinout Longboard to house trio of neuroscience programs

...“generated evidence in the same patient population as Fintepla,” the oral fenfluramine solution marketed by Zogenix Inc....
BioCentury | Oct 17, 2020
Regulation

CHMP’s October recommendations

...juvenile onset forms of the disease.CHMP’s positive opinions also included MAAs for Fintepla fenfluramine from Zogenix Inc....
BioCentury | Aug 26, 2020
Product Development

Sizing up Ovid’s soticlestat among Dravet therapies

...and Fintepla fenfluramine from Zogenix Inc. (NASDAQ:ZGNX). Fintepla also fared better in Dravet than it did in Lennox-Gastaut (see “Zogenix’s...
...of all three biotechs slipped Tuesday: Ovid $0.04 to $6.34; GW $3.02 to $103.25; and Zogenix...
BioCentury | Jul 23, 2020
Product Development

Encoded to drive first gene therapy into clinic with GV-led $135M series D

...cannabidiol from GW Pharmaceuticals plc (NASDAQ:GWPH); Diacomit stiripentol from Laboratoires Biocodex; and Fintepla fenfluramine from Zogenix Inc....
BioCentury | Jun 27, 2020
Regulation

Boxed warning on Zogenix’s Dravet syndrome therapy could hamper market prospects

...approval of a resubmitted NDA for Fintepla to treat seizures associated with Dravet syndrome sets Zogenix...
...and older, will only be available through a risk evaluation and mitigation strategy (REMS) . Zogenix Inc....
...for the rare epilepsy (see “Zogenix’s Fintepla Falls Short in Phase III” ). Fintepla is Zogenix’s...
BioCentury | Apr 22, 2020
Management Tracks

Hershberg joins Frazier as venture partner; plus Moses to chair LabGenius, and ViralClear, MorphoSys, Emergent and more

...CMO; he will remain in the position until a successor is found. Rare disease company Zogenix Inc....
...temporarily assume the role of executive chairman. Robin Sawka, BioCentury Staff Frazier Healthcare Partners BioMarin Pharmaceutical Inc. Dicerna Pharmaceuticals Inc. Zogenix Inc. ADC...
BioCentury | Mar 6, 2020
Finance

March 5 Quick Takes: Zogenix, Karyopharm, BridgeBio, Cinclus, Culture Biosciences, Deerfield-Melinta

...Zogenix, Karyopharm price follow-ons Zogenix Inc. (NASDAQ:ZGNX) and Karyopharm Therapeutics Inc. (NASDAQ:KPTI) each priced follow-on offerings, raising...
...NASDAQ:ZGNX) and Karyopharm Therapeutics Inc. (NASDAQ:KPTI) each priced follow-on offerings, raising a combined $350.2 million. Zogenix...
...has continued to market its products since filing for Chapter 11 in December. BioCentury Staff BridgeBio Pharma Inc. Zogenix Inc. Karyopharm...
Items per page:
1 - 10 of 249
BioCentury | Dec 22, 2020
Regulation

Dec. 21-23 Regulatory Quick Takes: positive CHMP opinion for Pfizer-BioNTech COVID-19 vaccine; plus Urovant’s approval, a Feb. 9 adcomm for Keytruda in TNBC, NMPA reviewing a subcutaneous PD-L1, and more

...among international regulators. Zogenix’s Fintepla gains EU approval in DravetThe European Commission approved Fintepla fenfluramine from Zogenix Inc....
BioCentury | Dec 5, 2020
Product Development

Dec. 4 Quick Takes: Zogenix in Dravet deal with start-up; plus updates from BioCryst, Takeda, AB Science, Sutro, Lilly, Cedars-Sinai

...suppression. Tevard is eligible for $70-$100 million in milestones for each program. FDA has approved Zogenix's...
...Folate receptor 1 BC Staff maribavir (TAK-620, SHP620, 1263W94, Camvia) Masiviera, masitinib (AB1010, masican, masipro) STRO-002 bamlanivimab, LY-CoV555 (LY3819253) BioCryst Pharmaceuticals Inc. Zogenix Takeda Sutro...
BioCentury | Nov 12, 2020
Management Tracks

ObsEva, Korro bring in new CEOs; plus Cerebral, Spartan, Apnimed and Micronoma

...as chairman and Stephen Collins as a board member. Farr is co-founder, president and CEO of Zogenix Inc....
...VP of laboratory operations at DermTech Inc. (NASDAQ:DMTK). Danielle Golovin Aerpio Pharmaceuticals Inc. Nektar Therapeutics Spartan Bioscience Inc. ObsEva S.A. Cerebral Therapeutics Inc. Zogenix Inc. Xalud...
BioCentury | Oct 28, 2020
Deals

Out of the Arena: With $56M round, spinout Longboard to house trio of neuroscience programs

...“generated evidence in the same patient population as Fintepla,” the oral fenfluramine solution marketed by Zogenix Inc....
BioCentury | Oct 17, 2020
Regulation

CHMP’s October recommendations

...juvenile onset forms of the disease.CHMP’s positive opinions also included MAAs for Fintepla fenfluramine from Zogenix Inc....
BioCentury | Aug 26, 2020
Product Development

Sizing up Ovid’s soticlestat among Dravet therapies

...and Fintepla fenfluramine from Zogenix Inc. (NASDAQ:ZGNX). Fintepla also fared better in Dravet than it did in Lennox-Gastaut (see “Zogenix’s...
...of all three biotechs slipped Tuesday: Ovid $0.04 to $6.34; GW $3.02 to $103.25; and Zogenix...
BioCentury | Jul 23, 2020
Product Development

Encoded to drive first gene therapy into clinic with GV-led $135M series D

...cannabidiol from GW Pharmaceuticals plc (NASDAQ:GWPH); Diacomit stiripentol from Laboratoires Biocodex; and Fintepla fenfluramine from Zogenix Inc....
BioCentury | Jun 27, 2020
Regulation

Boxed warning on Zogenix’s Dravet syndrome therapy could hamper market prospects

...approval of a resubmitted NDA for Fintepla to treat seizures associated with Dravet syndrome sets Zogenix...
...and older, will only be available through a risk evaluation and mitigation strategy (REMS) . Zogenix Inc....
...for the rare epilepsy (see “Zogenix’s Fintepla Falls Short in Phase III” ). Fintepla is Zogenix’s...
BioCentury | Apr 22, 2020
Management Tracks

Hershberg joins Frazier as venture partner; plus Moses to chair LabGenius, and ViralClear, MorphoSys, Emergent and more

...CMO; he will remain in the position until a successor is found. Rare disease company Zogenix Inc....
...temporarily assume the role of executive chairman. Robin Sawka, BioCentury Staff Frazier Healthcare Partners BioMarin Pharmaceutical Inc. Dicerna Pharmaceuticals Inc. Zogenix Inc. ADC...
BioCentury | Mar 6, 2020
Finance

March 5 Quick Takes: Zogenix, Karyopharm, BridgeBio, Cinclus, Culture Biosciences, Deerfield-Melinta

...Zogenix, Karyopharm price follow-ons Zogenix Inc. (NASDAQ:ZGNX) and Karyopharm Therapeutics Inc. (NASDAQ:KPTI) each priced follow-on offerings, raising...
...NASDAQ:ZGNX) and Karyopharm Therapeutics Inc. (NASDAQ:KPTI) each priced follow-on offerings, raising a combined $350.2 million. Zogenix...
...has continued to market its products since filing for Chapter 11 in December. BioCentury Staff BridgeBio Pharma Inc. Zogenix Inc. Karyopharm...
Items per page:
1 - 10 of 249